End-stage Renal Disease (ESRD) Pilot Study

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

September 15, 2021

Study Completion Date

September 15, 2021

Conditions
Renal Dialysis
Interventions
DRUG

BAY1213790

Single intravenous infusion of BAY1213790 (Two different doses)

DRUG

0.9% sodium chloride solution

Single intravenous infusion of Placebo (0.9% sodium chloride solution)

Trial Locations (15)

1090

UZ Brussel, Bruxelles - Brussel

3000

UZ Leuven Gasthuisberg, Leuven

6042

CHU de Charleroi Hôpital civil, Lodelinsart

14004

Hospital Reina Sofía, Córdoba

15706

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

34209

Nova Clinical Research, LLC, Bradenton

46010

Hospital Clínico Universitario de Valencia, Valencia

46017

Hospital Universitario Dr. Peset, Valencia

60643

Research by Design, LLC, Chicago

91910

California Institute of Renal Research - Chula Vista, Chula Vista

01107

Renal and Transplant Associates of New England, PC, Springfield

2795-53

CHLO - Hospital Santa Cruz, Carnaxide

2750-663

Pluribus Dialise - Cascais (DaVita), Cascais

2350-754

CHMT - Hospital Rainha Santa Isabel, Torres Novas

08907

Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY